In the recombinant pertussis vaccine, FHA is co-eluted with non-toxic genetically-detoxified PT and therefore is not exposed to chemical inactivation processes, resulting in retaining the functional and immunological properties of FHA. The gene discussed is F2; the disease is pertussis.